Avraham Eisbruch

List of Publications by Year in Descending Order

190 papers	15,736 citations	63 h-index	123 g-index
200 ext. papers	17,972 ext. citations	3.1 avg, IF	6.12 L-index

#	Paper	IF	Citations
190	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials.. *Clinical and Translational Radiation Oncology*, **2022**, 33, 30-36	4.6	
189	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. *Cancers*, **2022**, 14, 2587	6.6	0
188	Contemporary management of the neck in nasopharyngeal carcinoma. *Head and Neck*, **2021**, 43, 1949-1963	4.2	0
187	Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. *Cancers*, **2021**, 13,	6.6	3
186	Early MRI Blood Volume Changes in Constrictor Muscles Correlate With Postradiation Dysphagia. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 566-573	4	2
185	CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy. *Radiotherapy and Oncology*, **2021**, 155, 174-181	5.3	1
184	Long-term neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. *Head and Neck* , **2021**, 43, 1621-1628	4.2	0
183	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. *Oral Oncology*, **2021**, 121, 105332	4.4	3
182	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. *Head and Neck*, **2020**, 42, 1728-1737	4.2	1
181	Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma. *Oral Oncology*, **2020**, 111, 104853	4.4	7
180	Radiotherapy in the management of glottic squamous cell carcinoma. *Head and Neck*, **2020**, 42, 3558-3567	4.2	3
179	Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics. *Radiotherapy and Oncology*, **2020**, 148, 30-37	5.3	4
178	Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. *Cancer Treatment Reviews*, **2019**, 78, 42-51	14.4	10
177	Automatic recognition and analysis of metal streak artifacts in head and neck computed tomography for radiomics modeling. *Physics and Imaging in Radiation Oncology*, **2019**, 10, 49-54	3.1	12
176	Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. *Radiotherapy and Oncology*, **2019**, 137, 167-174	5.3	13
175	Predictive Models to Determine Clinically Relevant Deviations in Delivered Dose for Head and Neck Cancer. *Practical Radiation Oncology*, **2019**, 9, e422-e431	2.8	7
174	Utilizing skin sparing technique in HN VMAT treatment planning. *Medical Dosimetry*, **2019**, 44, 155-158	1.3	

173	Real-Time Quantitative Assessment of Accuracy and Precision of Blood Volume Derived from DCE-MRI in Individual Patients During a Clinical Trial. *Tomography*, **2019**, 5, 61-67	3.1	5
172	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. *Head and Neck*, **2019**, 41, 857-864	4.2	18
171	Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer. *Frontiers in Oncology*, **2019**, 9, 1118	5.3	11
170	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. *Lancet, The*, **2019**, 393, 40-50	40	546
169	Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era. *Cancer*, **2019**, 125, 68-78	6.4	6
168	Volumetric F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. *Head and Neck*, **2019**, 41, 366-373	4.2	11
167	Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. *Head and Neck*, **2018**, 40, 1375-1388	4.2	15
166	Radiation-induced carotid artery lesions. *Strahlentherapie Und Onkologie*, **2018**, 194, 699-710	4.3	27
165	Parameters Associated With Mandibular Osteoradionecrosis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 1276-1280	2.7	12
164	Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 969-977	4	11
163	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. *Radiotherapy and Oncology*, **2018**, 126, 68-74	5.3	41
162	Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. *Seminars in Radiation Oncology*, **2018**, 28, 46-52	5.5	27
161	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 1143-1169	2.2	108
160	Early Changes in Serial CBCT-Measured Parotid Gland Biomarkers Predict Chronic Xerostomia After Head and Neck Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 1319-1329	4	20
159	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 355-366	3.9	21
158	Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 170-176	4	4
157	Positron emission tomography-CT prediction of occult nodal metastasis in recurrent laryngeal cancer. *Head and Neck*, **2017**, 39, 980-987	4.2	12
156	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. *Practical Radiation Oncology*, **2017**, 7, 246-253	2.8	55

155	Head and Neck Radiation Therapy Sequelae and Late Complications and the Role of IMRT **2017**, 335-348		
154	Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. *JAMA Oncology*, **2017**, 3, 414-416	13.4	2
153	Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. *Otolaryngology - Head and Neck Surgery*, **2017**, 157, 625-630	5.5	4
152	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. *Otolaryngology - Head and Neck Surgery*, **2017**, 157, 995-997	5.5	1
151	Treatment of late sequelae after radiotherapy for head and neck cancer. *Cancer Treatment Reviews*, **2017**, 59, 79-92	14.4	105
150	E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma. *Clinical Cancer Research*, **2017**, 23, 2723-2729	12.9	21
149	Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards. *Advances in Radiation Oncology*, **2017**, 2, 503-514	3.3	14
148	Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. *Head and Neck*, **2016**, 38 Suppl 1, E805-14	4.2	33
147	IMRT for head and neck cancer: reducing xerostomia and dysphagia. *Journal of Radiation Research*, **2016**, 57 Suppl 1, i69-i75	2.4	60
146	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. *Laryngoscope*, **2016**, 126, E292-9	3.6	14
145	The big data effort in radiation oncology: Data mining or data farming?. *Advances in Radiation Oncology*, **2016**, 1, 260-271	3.3	38
144	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. *Head and Neck*, **2016**, 38 Suppl 1, E2151-8	4.2	107
143	Impact of xerostomia on dysphagia after chemotherapy-intensity-modulated radiotherapy for oropharyngeal cancer: Prospective longitudinal study. *Head and Neck*, **2016**, 38 Suppl 1, E1605-12	4.2	29
142	Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?. *European Archives of Oto-Rhino-Laryngology*, **2016**, 273, 2925-30	3.5	9
141	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. *Head and Neck*, **2016**, 38, 184-90	4.2	29
140	Squamous Cell Carcinoma of the Tongue During Pregnancy: A Case Report and Review of the Literature. *Journal of Oral and Maxillofacial Surgery*, **2016**, 74, 2557-2566	1.8	12
139	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. *JAMA Otolaryngology - Head and Neck Surgery*, **2016**, 142, 313-8	3.9	7
138	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. *Oral Oncology*, **2016**, 54, 68-74	4.4	12

137	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. *European Archives of Oto-Rhino-Laryngology*, **2016**, 273, 2877-94	3.5	18
136	Intensity-Modulated and Image-Guided Radiation Therapy **2016**, 294-324.e5		1
135	Temporal Feature Extraction from DCE-MRI to Identify Poorly Perfused Subvolumes of Tumors Related to Outcomes of Radiation Therapy in Head and Neck Cancer. *Tomography*, **2016**, 2, 341-352	3.1	6
134	Normal Tissue Complications and Protection in Head and Neck Cancer Patients **2016**, 753-767		
133	Feasibility of Non-invasive Brain Modulation for Management of Pain Related to Chemoradiotherapy in Patients with Advanced Head and Neck Cancer. *Frontiers in Human Neuroscience*, **2016**, 10, 466	3.3	8
132	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. *Oral Oncology*, **2016**, 60, 32-40	4.4	22
131	Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer. *Head and Neck*, **2016**, 38, 1187-93	4.2	1
130	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. *Head and Neck*, **2016**, 38 Suppl 1, E1086-96	4.2	28
129	Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 354-361	4	46
128	Investigating the clinical significance of body composition changes in patients undergoing chemoradiation for oropharyngeal cancer using analytic morphomics. *SpringerPlus*, **2016**, 5, 429		12
127	Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 645-52	4	8
126	Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients. *Expert Review of Quality of Life in Cancer Care*, **2016**, 1, 361-371		3
125	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. *Radiotherapy and Oncology*, **2016**, 120, 81-6	5.3	41
124	Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. *Radiotherapy and Oncology*, **2015**, 116, 75-81	5.3	19
123	Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 925-33	4	63
122	Tumor Volumes and Prognosis in Laryngeal Cancer. *Cancers*, **2015**, 7, 2236-61	6.6	24
121	Sequelae of Therapy of Head and Neck Cancer: Their Prevention and Therapy **2015**, 215-248		
120	Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. *Head and Neck*, **2015**, 37, 8-11	4.2	14

119	Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. *Head and Neck*, **2014**, 36, 1233-40	4.2	32
118	Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. *Translational Oncology*, **2014**, 7, 479-83	4.9	4
117	Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	47
116	In reply to Ren et al. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 1214	4	
115	Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 973-980	4	30
114	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. *Oral Oncology*, **2014**, 50, 513-9	4.4	54
113	Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. *Head and Neck*, **2014**, 36, 120-5	4.2	72
112	MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?. *Radiology and Oncology*, **2014**, 48, 323-30	3.8	8
111	Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy. *Head and Neck*, **2014**, 36, 1589-1595	4.2	26
110	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. *Head and Neck*, **2014**, 36, 617-23	4.2	17
109	Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma. *JAMA Otolaryngology - Head and Neck Surgery*, **2014**, 140, 134-42	3.9	25
108	Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. *Head and Neck*, **2014**, 36, 431-43	4.2	83
107	Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. *Oral Oncology*, **2014**, 50, 234-9	4.4	49
106	Single or multi-channel vaginal cuff high-dose-rate brachytherapy: Is replanning necessary prior to each fraction?. *Practical Radiation Oncology*, **2014**, 4, 20-6	2.8	12
105	Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 580-8	4	91
104	Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia. *Medical Radiology*, **2014** , 167-188	0.2	
103	Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 935-40	4	137
102	Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. *Head and Neck*, **2013**, 35, 1083-90	4.2	23

101	Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. *Head and Neck*, **2013**, 35, 1323-30	4.2	20
100	Restoration of the orbital aesthetic subunit with the thoracodorsal artery system of flaps in patients undergoing radiation therapy. *Journal of Neurological Surgery, Part B: Skull Base*, **2013**, 74, 279-85	1.5	6
99	High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. *JAMA Otolaryngology - Head and Neck Surgery*, **2013**, 139, 1320-7	3.9	78
98	Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. *Laryngoscope*, **2012**, 122, 121-7	3.6	98
97	Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, e631-8	4	34
96	Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 1007-14	4	117
95	Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 1528-33	4	19
94	Normal tissue anatomy for oropharyngeal cancer: contouring variability and its impact on optimization. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, e245-9	4	28
93	Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. *Head and Neck*, **2012**, 34, 1727-33	4.2	64
92	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in advanced head-and-neck cancer. *Medical Physics*, **2012**, 39, 5277-85	4.4	48
91	Utility of pretreatment mean apparent diffusion coefficient and apparent diffusion coefficient histograms in prediction of outcome to chemoradiation in head and neck squamous cell carcinoma. *Journal of Computer Assisted Tomography*, **2012**, 36, 131-7	2.2	34
90	Conformal Therapy and Intensity-Modulated Radiation Therapy **2012**, 287-316		0
89	Delineating neck targets for intensity-modulated radiation therapy of head and neck cancer. *Frontiers of Radiation Therapy and Oncology*, **2011**, 43, 255-270		3
88	Safety considerations for IMRT: Executive summary. *Practical Radiation Oncology*, **2011**, 1, 190-5	2.8	34
87	Organ-sparing radiation therapy for head and neck cancer. *Nature Reviews Clinical Oncology*, **2011**, 8, 639-48	19.4	60
86	Recovery of salivary epidermal growth factor in parotid saliva following parotid sparing radiation therapy: a proof-of-principle study. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics*, **2011**, 111, 64-70		10
85	Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e93-9	4	187
84	Amifostine in the treatment of head and neck cancer: intravenous administration, subcutaneous administration, or none of the above. *Journal of Clinical Oncology*, **2011**, 29, 119-21	2.2	23

83	Normal Tissue Complications and Protection in Head and Neck Cancer Patients **2011**, 613-628		
82	Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. *JAMA Otolaryngology*, **2010**, 136, 1267-73		90
81	Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. *Journal of Clinical Oncology*, **2010**, 28, 2732-8	2.2	261
80	Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. *Clinical Cancer Research*, **2010**, 16, 1226-35	12.9	234
79	Clinical heterogeneity and tumor control probability. *Acta Oncologica*, **2010**, 49, 1385-7	3.2	1
78	HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. *Head and Neck*, **2010**, 32, 562-7	4.2	88
77	A comparison of dose-response models for the parotid gland in a large group of head-and-neck cancer patients. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1259-65	4	63
76	Radiation dose-volume effects in the larynx and pharynx. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S64-9	4	144
75	Radiation therapy and hearing loss. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S50-7	4	167
74	Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1333-8	4	256
73	Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 727-33	4	28
72	Radiotherapy dose-volume effects on salivary gland function. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S58-63	4	367
71	Parotid gland function after radiotherapy: the combined michigan and utrecht experience. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 449-53	4	124
70	Use of normal tissue complication probability models in the clinic. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S10-9	4	1027
69	The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S155-60	4	148
68	Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer. *Radiation Oncology*, **2010**, 5, 21	4.2	58
67	Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer. *Seminars in Radiation Oncology*, **2009**, 19, 43-52	5.5	46
66	Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. *Laryngoscope*, **2009**, 119, 1510-7	3.6	81

65	Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 725-33	4	59
64	A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. *Translational Oncology*, **2009**, 2, 184-90	4.9	124
63	Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study. *Radiotherapy and Oncology*, **2009**, 93, 510-5	5.3	71
62	Improving the Quality of Life of Patients with Head and Neck Cancer by Highly Conformal Radiotherapy. *Medical Radiology*, **2009**, 145-153	0.2	
61	Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. *Radiotherapy and Oncology*, **2008**, 89, 13-8	5.3	81
60	EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. *Journal of Clinical Oncology*, **2008**, 26, 3128-37	2.2	495
59	Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. *Journal of Clinical Oncology*, **2008**, 26, 3138-46	2.2	284
58	Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 1287-90	4	104
57	Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 373-82	4	175
56	Post-Radiation Dysphagia. *Medical Radiology*, **2008**, 67-79	0.2	2
55	The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 660-9	4	153
54	Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 396-402	4	213
53	Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 1289-98	4	379
52	Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S40-2	4	77
51	Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S109-11	4	84
50	Physical models and simpler dosimetric descriptors of radiation late toxicity. *Seminars in Radiation Oncology*, **2007**, 17, 108-20	5.5	47
49	A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 3116-23	2.2	134
48	Delineating neck targets for intensity- modulated radiation therapy of head and neck cancer. What we learned from marginal recurrences?. *Frontiers of Radiation Therapy and Oncology*, **2007**, 40, 193-207		17

47	Intensity-modulated radiation therapy for head and neck carcinoma. *Oncologist*, **2007**, 12, 555-64	5.7	95
46	Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine. *Oncologist*, **2007**, 12, 975-7	5.7	18
45	Future issues in highly conformal radiotherapy for head and neck cancer. *Journal of Clinical Oncology*, **2007**, 25, 1009-13	2.2	30
44	Reducing xerostomia by IMRT: what may, and may not, be achieved. *Journal of Clinical Oncology*, **2007**, 25, 4863-4	2.2	47
43	Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. *Journal of Clinical Oncology*, **2006**, 24, 593-8	2.2	201
42	Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. *Radiotherapy and Oncology*, **2006**, 79, 15-20	5.3	268
41	Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. *Journal of Clinical Oncology*, **2006**, 24, 2636-43	2.2	316
40	Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 445-53	4	122
39	Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. *Radiotherapy and Oncology*, **2005**, 77, 32-8	5.3	29
38	Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 1393-402	4	140
37	Testing new chemoradiation regimens for head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 5-6	4	4
36	Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 725-31	4	144
35	Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 1395-9	4	126
34	Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 1413-8	4	44
33	Intensity-modulated radiation therapy in the treatment of head and neck cancer. *Nature Clinical Practice Oncology*, **2005**, 2, 34-9		36
32	Reducing radiation-induced xerostomia with highly conformal radiotherapy techniques. *The Journal of Supportive Oncology*, **2005**, 3, 201-2		2
31	Dysphagia and aspiration following chemo-irradiation of head and neck cancer: major obstacles to intensification of therapy. *Annals of Oncology*, **2004**, 15, 363-4	10.3	33
30	Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 28-42	4	267

29	Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 1425-39	4	498
28	Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. *World Journal of Surgery*, **2003**, 27, 832-7	3.3	154
27	The prevention and treatment of radiotherapy - induced xerostomia. *Seminars in Radiation Oncology*, **2003**, 13, 302-8	5.5	22
26	How should we measure and report radiotherapy-induced xerostomia?. *Seminars in Radiation Oncology*, **2003**, 13, 226-34	5.5	109
25	Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. *Cancer Detection and Prevention*, **2003**, 27, 305-10		54
24	Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. *International Journal of Radiation Oncology Biology Physics*, **2003**, 57, 61-70	4	284
23	CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. *Radiotherapy and Oncology*, **2003**, 69, 227-36	5.3	519
22	Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. *Seminars in Radiation Oncology*, **2002**, 12, 238-49	5.5	174
21	Clinical aspects of IMRT for head-and-neck cancer. *Medical Dosimetry*, **2002**, 27, 99-104	1.3	39
20	Irradiation of paranasal sinus tumors, a delineation and dose comparison study. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 120-7	4	40
19	Intensity-modulated radiotherapy of head-and-neck cancer: encouraging early results. *International Journal of Radiation Oncology Biology Physics*, **2002**, 53, 1-3	4	45
18	Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics* , **2002**, 53, 23-8	4	393
17	Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. *Gynecologic Oncology*, **2002**, 84, 289-95	4.9	55
16	Head and neck cancer: advances in radiation treatment. *MedGenMed: Medscape General Medicine*, **2002**, 4, 16		
15	Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. *Journal of Clinical Oncology*, **2001**, 19, 792-9	2.2	121
14	Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2001**, 50, 695-704	4	551
13	Partial irradiation of the parotid gland. *Seminars in Radiation Oncology*, **2001**, 11, 234-9	5.5	68
12	Radiosensitization produced in vivo by once- vs. twice-weekly 2S2Sdifluoro-2Sdeoxycytidine (gemcitabine). *International Journal of Radiation Oncology Biology Physics*, **2000**, 47, 785-91	4	67

11	Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 1117-26	4	300
10	Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study. *Journal of Clinical Oncology*, **1999**, 17, 31-40	2.2	11
9	Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **1999**, 45, 577-87	4	744
8	The influence of pre-radiation salivary flow rates and radiation dose on parotid salivary gland dysfunction in patients receiving radiotherapy for head and neck cancers. *Special Care in Dentistry*, **1998**, 18, 102-8	1.7	25
7	Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. *International Journal of Radiation Oncology Biology Physics*, **1998**, 41, 559-68	4	169
6	Spinal cord dose from standard head and neck irradiation: implications for three-dimensional treatment planning. *Radiotherapy and Oncology*, **1998**, 47, 185-9	5.3	15
5	Design and analysis of an immobilization and repositioning system for treatment of neck malignancies. *Medical Dosimetry*, **1997**, 22, 293-7	1.3	15
4	Planned early neck dissection before radiation for persistent neck nodes after induction chemotherapy. *Laryngoscope*, **1997**, 107, 1129-37	3.6	12
3	What a surgeon needs to know about radiation. *Annals of Surgical Oncology*, **1997**, 4, 516-22	3.1	2
2	Ipsilateral parotid sparing study in head and neck cancer patients who receive radiation therapy: results after 1 year. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics*, **1996**, 81, 642-8		31
1	Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. *International Journal of Radiation Oncology Biology Physics*, **1996**, 36, 469-80	4	173